| Document |
Document Title |
|
WO/2016/117298A1 |
Provided is a novel crystalline polymorphism of an inclusion compound (molar ratio 1:1) comprising 5-hydroxyisophthalic acid and 2-ethyl-4-methyl imidazole. A novel crystalline polymorphism of an inclusion compound (molar ratio 1:1) comp...
|
|
WO/2016/112875A2 |
The present invention relates to a diphenyl derivative and uses thereof, the diphenyl derivative having the structure as indicated in formula (I) defined in the description. The uses refer to the uses of the diphenyl derivative, pharmace...
|
|
WO/2016/114668A1 |
The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a p...
|
|
WO/2016/081658A1 |
Methods for making prodrugs of trepreostinil and treprostinil derivatives are provided. Specifically, methods are provided herein for producing prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, br...
|
|
WO/2016/034126A1 |
A compound of formula (I) is disclosed, which has a low toxicity, can significantly inhibit the migration and invasion of tumor cells in vitro, and can inhibit tumor metastasis in vivo in mice at low concentration, while showing notable ...
|
|
WO/2016/016641A1 |
A quaternary ammonium salt of formula wherein each of R1, R2, R3 and R4 is independently selected from an optionally substituted alkyl, alkenyl or aryl group having less than 8 carbon atoms and R5 is hydrogen or an optionally substituted...
|
|
WO/2016/011319A1 |
The present technology relates to synthesis of compositions comprising salicylates, polysalicylates and other derivatives of salicylic acid, and personal care and pharmaceutical compositions comprising the same.
|
|
WO/2015/175984A1 |
Described herein are compounds which can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, treating wounds, or other medical and/or cosmetic uses.
|
|
WO/2015/169854A1 |
The invention provides a method for the preparation of regioisomerically pure intermediates which are useful for the preparation of carboxy-fluorescein-type compounds. Such compounds have broad applications within bio-conjugation and/or ...
|
|
WO/2015/159098A1 |
There are provided compounds of the formula D-S1-A-S2-B1 wherein A comprises a 2,7- disubstituted 9,9-fluoroalkyl fluorene diradical of the formula wherein S1, S2, D and B1 have meanings given in the description that are useful as charge...
|
|
WO/2015/157082A1 |
Disclose are methods for minimizing the recycle of para-toluic acid within a terephthalic acid purification plant. Specifically, the disclosed methods remove a portion of the p-toluic acid from the pure plant flash condensate and recycle...
|
|
WO/2015/157239A1 |
The disclosure provides for metal organic frameworks (MOFs) which comprise a plurality of SBUs linked together by functionalized or multivariate BTB-based linking ligands. The disclosure further provides for the use of these MOFs in vari...
|
|
WO/2015/157187A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2015/137272A1 |
The present invention provides a porous structure containing at least two kinds of metal ions and an organic ligand, said porous structure being characterized in that the at least two kinds of metal ions are homogeneously mixed together ...
|
|
WO/2015/124651A1 |
The present invention relates to a process for providing a compound of formula (IV):wherein R1 and R2 are each independently C1-C4 alkyl, and Hal is independently Cl or Br, the process comprising the steps of: (i) reacting a compound of ...
|
|
WO/2015/120115A1 |
Compositions for use in methods of treating and/or inhibiting a pathologic ocular condition, as well as methods of producing and using same, are disclosed.
|
|
WO/2015/110502A1 |
A composition comprising a polymer, or an oligomer, comprising cross-linking moiety, which moiety comprises a carbon-carbon triple bond; and a molecule comprising a carbon-carbon triple bond, wherein the thermal curing behavior of said m...
|
|
WO/2015/092720A1 |
Provided herein are metabolites of N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)- 2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide
(Sonidegib, LDE225) that modulate the activity of the Hedgehog signaling pathway and tha...
|
|
WO/2015/086698A1 |
The present invention relates to a process for providing dihalogen substituted salicylic acid derivativesof formula (II).
|
|
WO/2015/078920A1 |
The present invention relates to a process for depolymerization of lignin, comprising a step of oxidation of non-phenolic lignin by bringing together, in at least one solvent, non-phenolic lignin, laccase, a redox mediator and an oxygen ...
|
|
WO/2015/067494A1 |
The present invention relates to a process for providing: a compound of formula (IV): wherein R1 is hydrogen or -(C1-C4)alkyl, R2 is -(C1-C4)alkyl, and each Hal is an independently selected halogen, the process comprising the step of: Re...
|
|
WO/2015/066693A1 |
The disclosure provides for Metal-Organic Frameworks comprising M2 (m-dobdc) -based cores, and methods of use thereof, including gas separation, gas storage, sensing, and other applications utilizing a high density of exposed metal catio...
|
|
WO/2015/055116A1 |
An in-depth study is performed on selaginella pulvinata extractives in the present invention, and it is found that the selaginella pulvinata extractives have a significant anti-inflammatory activity. Multiple column chromatography separa...
|
|
WO/2015/027669A2 |
Disclosed are a phenyl-substituted compound with structures represented by formula (1) and formula (2), a pharmaceutical composition and uses thereof. The compound can remarkably show in vivo and in vitro that the compound can kill and/o...
|
|
WO/2015/010666A2 |
A phenol derivative and a use thereof are disclosed. The phenol derivative comprises a compound as represented by structural formulas (I), (II) or (III) or a pharmaceutically acceptable salt, ester and amide thereof. In structural formul...
|
|
WO/2015/007181A1 |
Disclosed are 5-bromine-2-(α-hydroxypentyl)benzoic acid sodium salts in different crystal forms, and a preparation method thereof, relating to the field of medicinal chemistry. The 5-bromine-2-(α-hydroxypentyl)benzoic acid sodium salts...
|
|
WO/2015/002151A1 |
Provided is a method for stabilizing DHNA or a vitamin contained in a food, a beverage and or like under an environment which can be subjected to natural light or artificial light, e.g., a transparent container, without requiring the use...
|
|
WO/2014/208632A1 |
The present invention addresses the problem of providing: a base generator which has high solubility in widely used organic solvents, can be dissolved directly in a base-reactive compound such as an epoxy compound, has both high heat res...
|
|
WO/2014/205392A1 |
Disclosed herein are cocrystals of dimethyl fumarate and gentisic acid or (+)-camphoric acid. Dimethyl fumarate is a prodrug of methyl hydrogen fumarate. The cocrystals have improved physicochemical properties and are used in treating mu...
|
|
WO/2014/197195A2 |
The present disclosure is related to silica-based Lewis acid catalysts, being essentially devoid of strong Bronsted acid character, and their ability to effect the [4+2] cycloaddition and dehydrative aromatization of dienes and dienophil...
|
|
WO/2014/179263A1 |
The invention provides well-defined compounds, including compounds of the following formula, that are either EP2 agonists, EP4 agonists, or mixed EP2/EP4 agonist. The compounds are useful for treating a variety of pathological conditions...
|
|
WO/2014/177593A1 |
The present invention relates to Amorfrutin analogues and stereoisomeric forms, solvates, hydrates, conjugates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of ...
|
|
WO/2014/167017A1 |
The invention relates to a method for producing ortho-acylated aromatic or heteroaromatic carboxylic acids. According to the method, an aromatic or hetero-aromatic carboxylic acid or anhydride thereof, each of which has a CH group at the...
|
|
WO/2014/164636A1 |
Cosmetic compositions comprising salicylic acid dimers and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The salicylic acid derivatives are believed to have modulatory activity against one or...
|
|
WO/2014/164608A1 |
Cosmetic compositions comprising salicylic acid derivatives and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The salicylic acid derivatives are believed to have modulatory activity against o...
|
|
WO/2014/164630A1 |
Cosmetic compositions comprising salicylic acid derivatives and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The salicylic acid derivatives are believed to have modulatory activity against o...
|
|
WO/2014/123091A1 |
The object of the invention is to provide a method for producing a polymer having high solvent resistance and to provide a vinyl ester copolymer having high solvent resistance. Provided as a means for attaining the above object are: a me...
|
|
WO/2014/115915A1 |
The present invention relates to a novel reactive mesogen compound, and a preparation method therefor, and more specifically, to: a novel reactive mesogen compound which has an intrinsic liquid crystal characteristic of having a molecula...
|
|
WO/2014/095036A1 |
The invention relates to new compounds having fluorinated terminal groups of formula (I), use thereof as surface-active substances and agents containing said compounds, wherein X = a hydrophilic group, Y = linear or branched alkylene, wh...
|
|
WO/2014/097772A1 |
Provided is a method for obtaining an ionic metal complex salt that uses an organic compound as a ligand in which silicon tetrachloride is used as a reaction aid when reacting a metal complex salt containing a fluorine atom with an organ...
|
|
WO/2014/086723A1 |
The invention relates to the use of substituted 1 -(aryl ethynyl)-, 1 - (heteroaryl ethynyl)-, 1 -(heterocyclyl ethynyl)- and 1 -(cyloalkenyl ethynyl)- bicycloalkanols or salts thereof (I). The groups in general formula (I) correspond to...
|
|
WO/2014/078173A1 |
A compound of formula (I) wherein Rf is -CF3, -C2F5, or -CF2CFXCF3; X is -F, or -OC3F7; Y is -H, -Cl, or -Br; R is -OH, -(CH2)nOH, -(OCH2CH2)mOH, -(CH2)n(OCH2CH2)mOH, -O-C(O)-R1, -(CH2)nO-C(O)-R1, -(OCH2CH2)mOC(O)-R1, -C(O)NHw(CH2CH2OH)2...
|
|
WO/2014/069555A1 |
Provided is a compound that exhibits an excellent melanogenesis-inhibiting effect (skin-lightening effect), exhibits an excellent antimicrobial effect, excels in terms of temporal stability and the like, and is suitable for use as an ing...
|
|
WO/2014/016145A1 |
The invention relates to a method for producing at least one alkoxy-hydroxybenzaldehyde (AHBA) from at least one hydroxyphenol (HP), said method being characterised in that it comprises the formation of at least one alkoxyphenol (AP) and...
|
|
WO/2013/174916A1 |
Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the absolute stereochemistry and formula (I). In some cases R1 is leucine and R is selected from: OH, OC...
|
|
WO/2013/140506A1 |
Provided is a method for manufacturing 4,4'-oxydiphthalic acid with favorable productivity and high-yield via 4,4'-oxydiphthalonitrile, using 4-nitrophthalonitrile as a reaction raw material; the method including a hydrolysis step for hy...
|
|
WO/2013/129121A1 |
The problem to be solved by the present invention is to provide a liquid crystal composition which exhibits little haziness when subjected to liquid crystal alignment and made into a film, and with which cissing can be inhibited when a f...
|
|
WO/2013/101322A1 |
A process for oxidizing an alkyl-aromatic compound to reduce the level of impurities is described. The solvent pH level controlled to reduce the impurities.
|
|
WO/2013/101324A1 |
A process for oxidizing an alkyl-aromatic compound is described. The process includes oxidizing the alkyl-aromatic compound to produce a first oxidation product; contacting at least a portion of the first oxidation product, a solvent com...
|
|
WO/2013/101335A1 |
A process for oxidizing an alkyl-aromatic compound is described. The process includes contacting the alkyl-aromatic compound, a solvent comprising a precursor of at least one ionic liquid, a bromine source, a catalyst, and an oxidizing a...
|
